JP2010510784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510784A5 JP2010510784A5 JP2009538639A JP2009538639A JP2010510784A5 JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5 JP 2009538639 A JP2009538639 A JP 2009538639A JP 2009538639 A JP2009538639 A JP 2009538639A JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- receptor
- antibody
- sample
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86124306P | 2006-11-28 | 2006-11-28 | |
| US60/861,243 | 2006-11-28 | ||
| EP06024658 | 2006-11-28 | ||
| EP06024658.4 | 2006-11-28 | ||
| PCT/EP2007/010335 WO2008064884A1 (en) | 2006-11-28 | 2007-11-28 | Activated her3 as a marker for predicting therapeutic efficacy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510784A JP2010510784A (ja) | 2010-04-08 |
| JP2010510784A5 true JP2010510784A5 (https=) | 2011-01-20 |
| JP5656406B2 JP5656406B2 (ja) | 2015-01-21 |
Family
ID=38961070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538639A Active JP5656406B2 (ja) | 2006-11-28 | 2007-11-28 | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100047829A1 (https=) |
| EP (2) | EP2097754B2 (https=) |
| JP (1) | JP5656406B2 (https=) |
| AU (1) | AU2007324868B2 (https=) |
| CA (1) | CA2670522C (https=) |
| WO (1) | WO2008064884A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| ES2526211T3 (es) | 2007-07-13 | 2015-01-08 | Nestec S.A. | Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos |
| NZ617520A (en) | 2008-02-25 | 2015-05-29 | Nestec Sa | Drug selection for breast cancer therapy using antibody-based arrays |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| UA104868C2 (uk) | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
| US8652787B2 (en) | 2008-11-12 | 2014-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of ERBB4 as a prognostic and therapeutic marker for melanoma |
| AU2010273319B2 (en) | 2009-07-15 | 2015-01-22 | Nestec S.A. | Drug selection for gastric cancer therapy using antibody-based arrays |
| US20120270745A1 (en) * | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| CA2792327C (en) | 2010-03-11 | 2019-09-24 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
| EP2590654B1 (en) | 2010-07-09 | 2016-12-21 | Exelixis, Inc. | Combinations of kinase inhibitors for the treatment of cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| JP6186575B2 (ja) | 2011-09-02 | 2017-08-30 | ダイアテック ホールディングス， インコーポレイテッドＤｉａＴｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｉｎｃ． | 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング |
| ES2670651T3 (es) * | 2011-10-04 | 2018-05-31 | Expression Pathology, Inc. | Ensayo de SRM/MRM para determinar la proteína ERBB-4 del receptor de tirosina-proteína quinasa (HER4) |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| KR101524915B1 (ko) | 2013-05-10 | 2015-06-02 | 포항공과대학교 산학협력단 | 타이로신 인산화효소를 감지하는 형광 프로브 및 이의 용도 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| IL126303A (en) | 1996-03-27 | 2002-05-23 | Genentech Inc | ErbB3 ANTIBODIES |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| CA2432276A1 (en) * | 2000-12-22 | 2002-08-01 | Dana-Farber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US20040018528A1 (en) * | 2002-05-17 | 2004-01-29 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
| KR20050037510A (ko) * | 2002-06-05 | 2005-04-22 | 세다르스-신나이 메디칼 센터 | 키나제 억제제를 사용하는 암 치료 방법 |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ， インコーポレイテッド | レセプターオリゴマー形成の検出 |
| CA2521077A1 (en) | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Erbb surface receptor complexes as biomarkers |
| JP4724657B2 (ja) * | 2003-05-30 | 2011-07-13 | アストラゼネカ ユーケー リミテッド | プロセス |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
| WO2005117553A2 (en) * | 2004-05-27 | 2005-12-15 | The Regents Of The University Of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2007
- 2007-11-28 JP JP2009538639A patent/JP5656406B2/ja active Active
- 2007-11-28 EP EP07846863.4A patent/EP2097754B2/en active Active
- 2007-11-28 WO PCT/EP2007/010335 patent/WO2008064884A1/en not_active Ceased
- 2007-11-28 US US12/516,682 patent/US20100047829A1/en not_active Abandoned
- 2007-11-28 EP EP12176507A patent/EP2518508A1/en not_active Withdrawn
- 2007-11-28 CA CA2670522A patent/CA2670522C/en active Active
- 2007-11-28 AU AU2007324868A patent/AU2007324868B2/en active Active
-
2016
- 2016-02-18 US US15/047,041 patent/US10365283B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510784A5 (https=) | ||
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| Morris et al. | HER‐2 profiling and targeting in prostate carcinoma: A Phase II trial of trastuzumab alone and with paclitaxel | |
| JP5656406B2 (ja) | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ | |
| Resnick et al. | Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study | |
| Kazemi et al. | VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans | |
| Go et al. | Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma | |
| Schmitz et al. | Window of opportunity studies: do they fulfil our expectations? | |
| KR20140002711A (ko) | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 | |
| Lee et al. | Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab | |
| Johnson et al. | Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma | |
| Millanta et al. | Immunohistochemical expression of COX-2, mPGES and EP2 receptor in normal and reactive canine bone and in canine osteosarcoma | |
| WO2013126147A2 (en) | Elevated psma identifies lethal prostate cancers | |
| JP2016517960A5 (https=) | ||
| JP2009516178A5 (https=) | ||
| JP5413818B2 (ja) | 蛍光多重染色による蛋白定量法 | |
| Kossatz et al. | PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers–first-in-human results | |
| Bozzi et al. | Evidence for activation of KIT, PDGFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors | |
| JP2011527575A5 (https=) | ||
| RuizdelRio et al. | Profibrotic role of inducible heat shock protein 90α isoform in systemic sclerosis | |
| George | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor | |
| Serrero | Potential of theranostic target mining in the development of novel diagnostic and therapeutic products in oncology: progranulin/GP88 as a therapeutic and diagnostic target for breast and lung cancers | |
| CN103562722A (zh) | 一种区分甲状腺癌变的方法、实施该方法的试剂盒以及金属硫蛋白在区分甲状腺癌变中的用途 | |
| Sevinc et al. | The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective | |
| Dlamini | Navigating Melanoma Treatment Challenges: Next-generation Strategies and Solutions |